- mAbxience has selected the Genedata Bioprocess enterprise platform to structure and harmonize bioprocess development data across its operations.
- The SaaS-based system will automate workflows and integrate experimental and process data to support biosimilar development and CDMO contract manufacturing activities.
mAbxience has selected the Genedata Bioprocess enterprise platform to structure and harmonize bioprocess development data across its operations. The company operates as a contract development and manufacturing organization (CDMO) focused on biosimilars and is majority-owned by the Fresenius Kabi group.
The Genedata Bioprocess platform will be implemented as a SaaS solution through the Genedata Cloud. The system is designed to integrate data across upstream and downstream processing, cell line development, formulation, and analytical development. According to the companies, the platform will consolidate experimental and process data into a centralized environment for managing bioprocess workflows.
“With our growing biosimilars portfolio and increasing complexity in bioprocess development, we needed a single, integrated platform that connects and analyzes all data across upstream, downstream, cell line, formulation, and analytical development.”
Ivan Sánchez de Melo, Ph.D., R&D Director at mAbxience
By deploying the enterprise platform, the company aims to automate end-to-end workflows and support collaboration across development teams. The system is intended to provide data traceability and integrity while enabling faster decision-making and documentation across contract manufacturing and development operations.
Genedata stated that the platform will create a unified digital environment for bioprocess data management and support further steps such as process modeling and AI-driven optimization. The implementation is expected to help mAbxience scale operations and manage the growing complexity associated with biosimilar development.
